About Cardiac Defibrillator
A defibrillator device that is implanted is implanted under the skin on the side of the chest below the arm pit. The pulse generator is associated with the electrode which is fixed under the skin from the device pocket along the rib margin to the breastbone with the use of the insertion tool. The use of implantable cardiac defibrillators (ICDs) to avoid sudden cardiac death (SCD) in patients resuscitated from cardiac arrest or documented hazardous ventricular arrhythmias is an insured service. The biggest trends in ICD technology have been a movement to smaller devices, simplified implantation, and reducing or eliminating leads implanted in the veins or the heart.
Attributes | Details |
---|
Study Period | 2017-2027 |
Base Year | 2021 |
Unit | Value (USD Million) |
Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Cardiac Defibrillator market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Medtronic (Ireland), Boston Scientific Corporation (United States), Biotronik (Germany), LivaNova Plc (United Kingdom), Abbott (United States), Microport (China), Imricor Medical Systems, Inc. (United States), St. Jude Medical, Inc. (United States), Koninklijke Philips N.V. (Netherlands) and ZOLL Medical Corporation (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Fukuda Denshi Co., Ltd. (Japan), Progetti Srl (Italy) and HeartSine Technologies (United States).
Segmentation Overview
AMA Research has segmented the market of Global Cardiac Defibrillator market by Type (Implantable Cardioverter Defibrillator [S-ICD, T-ICD] and External Defibrillator [Manual, Automated, Wearable]), Application (Hospitals, Specialty Clinics and Ambulatory Surgical Centers) and Region.
On the basis of geography, the market of Cardiac Defibrillator has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Cardiac Defibrillator Market Dynamics:
Attributes | Details |
---|
Growth Drivers | - Rising Demand for Handling Cardiovascular Conditions
- Increasing Prevalence of Lifestyle Diseases, Such As Cardiac Disorders
|
Influencing Trends | - Innovation with Regards to Implantable Devices
|
Restraints | - Major Risks of Long-Term ICD Therapy Lead to Failure
|
Road Blocks / Challenges | - Device Replacement Is Associated With Significant Morbidity and Some Mortality
|
Gaps & Opportunities | - Rising Demand for Treatment of Sudden Cardiac Arrest SCA
- Increasing Demand for Home Care and Alternate Care Defibrillators
|
Market Leaders and their expansionary development strategies
On June 27, 2019 - Medtronic plc, a global leader in medical technology, announced that it has completed the acquisition of Titan Spine, a privately-held titanium spine interbody implant and surface technology company. The acquisition of Titan Spine strengthens Medtronic’s position as a leading innovator in procedural solutions for spine surgery. and On July 22, 2019 - ZOLL Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced that it has acquired substantially all of the assets of Mobilize RRS LLC., of Pittsford, N.Y.
In April 2019 - Biotronik launched the Acticor device family of new ICDs and cardiac resynchronization therapy defibrillators (CRT-Ds). BIOTRONIK today announced the launch of its Acticor 7 ICD and CRT-D families, which offer a variety of features that specifically address the needs of Japanese patients. The devices are only 10 mm slim and come with an elliptical BIOshape as well as longer battery life. and On March 11, 2019 - BIOTRONIK today announced the European market release of the world’s smallest ICD and CRT-D devices that are approved for 3 Tesla (3T) full-body MRI scans. Devices in the Acticor and Rivacor families are only 10 mm slim, with a smooth and elliptical BIOshape that facilitates the insertion procedure.
Key Target Audience
Manufacturers of Cardiac Defibrillator Devices, Suppliers of Cardiac Defibrillator Devices, Wholesalers, Distributors and Retailers of Cardiac Defibrillator Devices, Healthcare Industry, Research Organization and Governmental Bodies
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.